AMTI News and Press, Applied Molecular Transport Inc. From 11/15/21

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Bittoo Kanwar, M.D., chief medical officer, and Liz Bhatt, chief business and strategy officer, will partici...

Applied Molecular Transport (NASDAQ:AMTI): Q3 GAAP EPS of -$0.68 misses by $0.06. Cash, cash equivalents and investments of $182.5M Press Release For further details see: Applied Molecular Transport EPS misses by $0.06

Top-line data readout for oral AMT-101 Phase 2 MARKET combination trial with anti-TNF α in ulcerative colitis (UC) expected in H1 2022 Top-line data readouts from three additional oral AMT-101 Phase 2 trials, consistent with previous guidance FILLMORE mo...

Management to highlight novel oral biologics technology platform, clinical programs and research activities Feature distinguished IBD and rheumatology key opinion leaders Provide update on the four on-going Phase 2 clinical trials for oral AMT-101 SOUTH SAN FRANCIS...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the following investor events in September and October. Details of th...

SOUTH SAN FRANCISCO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Holly Schachner, M.D. a seasoned and accomplished industry veteran to its Board of Directors. ...

Top-line data readouts expected from four Phase 2 trials of oral AMT-101, consistent with previous guidance Combination trial of AMT-101 with anti-TNF α in moderate-to-severe ulcerative colitis (UC) patients in the fourth quarter of 2021; Monotherapy tri...

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during Can...

Applied Molecular Transport (AMTI) announces additional Phase 1b data for oral AMT-101 in ulcerative colitis ((UC)) patients.The Phase 1b multiple ascending dose trial evaluated safety and was a randomized, placebo-controlled 3:1, double-blind trial that included 16 patients with active ...